8 May 2024 in International Journal of Surgery
Background: Previous trials confirmed the benefit of endovascular treatment (EVT) in acute large core stroke, but the effect of EVT on outcomes in these patients based on noncontrast computed tomography (NCCT) in real-world clinical practice was unclear. The aim of this study was to explore the effect of EVT versus standard medical treatment (SMT) in patients with large ischemic core stroke defined as Alberta Stroke Program Early CT Score (ASPECTS) ≤5 based on NCCT alone. Materials and methods: Patients with acute large core stroke at 38 Chinese centers between November 2021 and February 2023 were reviewed from a prospectively maintained database. The primary outcome was favorable functional outcome [modified Rankin Scale score (mRS), 0–3] at 90 days. Safety outcomes included 48 h symptomatic intracerebral hemorrhage (sICH) and 90-day mortality. Results: Of 745 eligible patients recruited at 38 stroke centers between November 2021 and February 2023, 490 were treated with EVT+SMT and 255 with SMT alone. One hundred and eighty-one (36.9%) in the EVT group achieved favorable functional independence versus 48 (18.8%) treated with SMT only [adjusted risk ratio (RR), 1.86; 95% CI: 1.43–2.42, P<0.001; adjusted risk difference (RD), 13.77; 95% CI: 7.40–20.15, P<0.001]. The proportion of sICH was significantly higher in patients undergoing EVT (13.3 vs. 2.4%; adjusted RR, 5.17; 95% CI: 2.17–12.32, P<0.001; adjusted RD, 10.10; 95% CI: 6.12–14.09, P<0.001). No significant difference of mortality between the groups was observed (41.8 vs. 49.0%; adjusted RR, 0.91; 95% CI: 0.77–1.07, P=0.24; adjusted RD, −5.91; 95% CI: −12.91–1.09, P=0.1). Conclusion: Among patients with acute large core stroke based on NCCT in real-world, EVT is associated with better functional outcomes at 90 days despite of higher risk of sICH. Rates of procedure-related complications were relatively higher in the EVT+SMT group.
30 August 2023 in Annals of Clinical and Translational Neurology
Objective: This study aimed to investigate whether treatment with adjunct intravenous tirofiban is associated with improved outcomes following successful reperfusion in patients with intracranial atherosclerotic stroke.Methods: Patients with intracranial large artery atherosclerotic (LAA) stroke and an expanded Treatment in Cerebral Ischemia angiographic score of 2b50 to 3 from the Effect of Intravenous Tirofiban versus Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke (RESCUE BT) trial were included. The primary outcome was the difference in proportion of independent functional outcome (modified Rankin score of 0–2 at 90 days). Safety outcomes included the rates of symptomatic intracranial hemorrhage (sICH) and 90‐day mortality.Results: Among the 382 patients with intracranial LAA stroke and successful reperfusion, 175 patients (45.8%) were treated with intravenous tirofiban and 207 (54.2%) with placebo. The proportion of patients with independent functional outcome at 90 days was 54.3% (95 out of 175) with tirofiban and 44.0% (91 out of 207) with placebo (adjusted odds ratio [aOR], 1.58; 95% CI, 1.02–2.44; p = 0.04). Intravenous tirofiban was not significantly associated with an increased risk of sICH (12/175 [6.9%] vs. 11/207 [5.3%]; aOR, 1.41; 95% CI, 0.59–3.34; p = 0.44) or 90‐day mortality (21/175 [12.0%] vs. 34/207 [16.4%]; aOR, 0.71; 95% CI, 0.38–1.31; p = 0.27).Interpretation: Among patients with acute intracranial LAA stroke and successful reperfusion following endovascular thrombectomy, adjunct intravenous tirofiban was associated with a higher rate of independent functional outcome, without higher rates of sICH or mortality. Confirmatory randomized trials in these patients are desirable.
20 April 2023 in American Journal of Neuroradiology
BACKGROUND AND PURPOSE: Endovascular treatment is a reference treatment for acute basilar artery occlusion (ABAO). However, no established and specific methods are available for the preoperative screening of patients with ABAO suitable for endovascular treatment. This study explores the potential value of DWI-based radiomics in predicting the functional outcomes of endovascular treatment in ABAO. MATERIALS AND METHODS: Patients with ABAO treated with endovascular treatment from the BASILAR registry (91 patients in the training cohort) and the hospitals in the Northwest of China (31 patients for the external testing cohort) were included in this study. The Mann-Whitney U test, random forests algorithm, and least absolute shrinkage and selection operator were used to reduce the feature dimension. A machine learning model was developed on the basis of the training cohort to predict the prognosis of endovascular treatment. The performance of the model was evaluated on the independent external testing cohort. RESULTS: A subset of radiomics features (n = 6) was used to predict the functional outcomes in patients with ABAO. The areas under the receiver operating characteristic curve of the radiomics model were 0.870 and 0.781 in the training cohort and testing cohort, respectively. The accuracy of the radiomics model was 77.4%, with a sensitivity of 78.9%, specificity of 75%, positive predictive value of 83.3%, and negative predictive value of 69.2% in the testing cohort. CONCLUSIONS: DWI-based radiomics can predict the prognosis of endovascular treatment in patients with ABAO, hence allowing a potentially better selection of patients who are most likely to benefit from this treatment.
29 April 2026 in Frontiers in Neurology
Objectives: Minimally invasive puncture and drainage (MIPD) is a safe and effective treatment for spontaneous intracerebral hemorrhage (sICH). However, the impact of time to evacuation on clinical outcomes remains unclear. This study aims to assess the association between the time from symptom onset to MIPD and long-term mortality. Methods: The study retrospectively included consecutive patients with a hematoma ≥ 20 mL who underwent MIPD within 24 h of symptom onset. Patients were stratified by different time windows (0–6 h, 6–12 h, and 12–24 h) from symptom onset to MIPD. One-year (long-term) mortality was defined as the primary outcome. Secondary outcomes included the incidence of rebleeding, the Glasgow Coma Scale (GCS) score at discharge, and modified Rankin Scale (mRS) scores at 3 and 6 months. The association between time to evacuation and clinical outcomes was assessed using multivariate logistic regression and inverse probability of treatment weighting (IPTW) analysis. Results: A total of 214 eligible patients were included in our study. Patients who underwent MIPD within 6 h or 6 to 12 h had a higher long-term mortality rate compared to those treated within 12 to 24 h (48.48, 50.56, and 30.34%, respectively; p = 0.02). In IPTW analysis, undergoing MIPD within 12–24 h of symptom onset was associated with reduced short-term mortality [odds ratio (OR), 0.519; 95%CI (0.290–0.929), p = 0.03] and long-term mortality [OR, 0.530; 95% CI (0.300–0.937), p = 0.03]. Conclusion: In patients with sICH, the time to MIPD within 12 to 24 h was associated with a decreased risk of long-term mortality.
4 September 2025 in Journal of Thrombosis and Thrombolysis